- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01417533
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases
Background:
- GNE Myopathy is a disease that causes walking difficulties and increasing muscle weakness. It usually develops in young adults (between 20 and 30 years of age), and affects arm and leg muscles. HIBM is caused by mutations in a gene that may affect how the muscles function. Researchers want to learn more about the causes, symptoms, and effects of HIBM.
Objectives:
- To collect genetic and medical information from people with GNE Myopathy .
Eligibility:
- Individuals between 18 and 80 years of age who have GNE Myopathy and do not use a wheelchair. - Participants must be willing to stop any current treatment of HIBM while enrolled in the study.
Design:
- Participants will be screened with a medical history, physical exam, and neurological exam.
- At the first visit, participants will have the following tests:
- Questionnaires about the impact of HIBM on daily activities, mood, and quality of life
- 24-hour urine collection
- Blood samples
- Heart function tests
- Muscle strength and endurance tests, including walking
- Imaging study of the muscles
- Participants will return for followup visits at 6, 12, and 18 months. They may be asked to return for a final visit at 24 months. Not all tests will be performed at each visit.
- Treatment will not be provided as part of this protocol.
For more information, visit our website: http://hibmstudy.nhgri.nih.gov/
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Andrea I Bowling, C.R.N.P.
- Phone Number: (301) 451-3824
- Email: andrea.bowling@nih.gov
Study Contact Backup
- Name: Francis Rossignol, M.D.
- Phone Number: (301) 402-2324
- Email: francis.rossignol@nih.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Recruiting
- National Institutes of Health Clinical Center
-
Contact:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- Phone Number: TTY dial 711 800-411-1222
- Email: ccopr@nih.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
INCLUSION CRITERIA:
- Age 4-80 years, either gender, inclusive.
- Diagnosis of GNE myopathy or GNE-related diseases based upon the identification of GNE gene mutations. Molecular confirmation of the diagnosis will be obtained for all subjects in the study.
- Subjects that are a carrier family member of a patient on the study are eligible to participate.
- Must be able to provide informed consent.
EXCLUSION CRITERIA:
- Psychiatric illness or other diseases that would interfere with the subject s ability to comply with the requirements of this protocol.
- Hepatic laboratory parameters (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) or renal laboratory parameters (creatinine, blood urea nitrogen [BUN]) greater than 3 times the upper limit of normal.
- Presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, or gastrointestinal disease not related to the primary disease process.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
GNE
Patients with a diagnosis of GNE myopathy
|
GNE-Related Diseases
Patient with a GNE related disease
|
non-GNE
Subjects that are a carrier family member or a caregiver of a patient on the study are eligibleto participate.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Natural History
Time Frame: Ongiong
|
To delineate the natural history of GNE myopathy, and to further characterize the phenotype, progression and complications of the disease.
|
Ongiong
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endpoints
Time Frame: Ongoing
|
To identify endpoints and biomarkers of the disease.
To study factors that contribute to disease heterogeneity.
|
Ongoing
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Francis Rossignol, M.D., National Human Genome Research Institute (NHGRI)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 110218
- 11-HG-0218
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GNE Myopathy
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyCanada, United States, Bulgaria
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyUnited States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka TypeUnited States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
-
Ultragenyx Pharmaceutical IncNewcastle UniversityCompletedHereditary Inclusion Body Myopathy | GNE Myopathy | Nonaka Disease | Quadriceps Sparing Myopathy (QSM) | Distal Myopathy With Rimmed Vacuoles (DMRV)United States, Bulgaria, Canada, France, United Kingdom
-
Ultragenyx Pharmaceutical IncCompletedGNE Myopathy | Hereditary Inclusion Body Myopathy (HIBM)United States, Israel
-
Newcastle UniversityUnknownHereditary Inclusion Body Myopathy | GNE MyopathyUnited Kingdom
-
NobelpharmaCompletedGNE Myopathy | Nonaka Disease | Distal Myopathy With Rimmed Vacuoles (DMRV) | Hereditary Inclusion Body Myopathy (hIBM)Japan
-
National Human Genome Research Institute (NHGRI)National Center for Advancing Translational Sciences (NCATS); Therapeutics...CompletedGNE Myopathy | Hereditary Inclusion Body Myopathy (HIBM)United States
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy | GNE MyopathyUnited States, Israel
-
National Human Genome Research Institute (NHGRI)National Center for Advancing Translational Sciences (NCATS)Completed